Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer

摘要: Abstract S-1 is an oral fluoropyrimidine derivative that active against non-small cell lung cancer (NSCLC). Development of combination chemotherapy for advanced NSCLC under way. Given the importance designing therapeutic strategies based on specific tumor biology, we have evaluated relation between immunohistochemical expression levels thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), or dihydropyrimidine dehydrogenase (DPD) and response to treatment with plus carboplatin in patients NSCLC. Chemotherapy-naive (stage IIIB IV) NSCLC, Eastern Cooperative Oncology Group performance status 0 1, adequate organ function, archival tissue were assigned receive S-1–carboplatin ( n  = 22). The predictive prognostic relevance molecular markers was also examined by their evaluation treated paclitaxel  = 25). Expression TS, OPRT, DPD specimens did not differ significantly those paclitaxel–carboplatin. A low level TS associated a better longer survival but Tumor are